Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
A 74-year-old man was referred to our hospital with an abnormal chest shadow. Computed tomography (CT) revealed a mass in the left upper lobe and interstitial pneumonia (IP). The patient underwent CT-guided needle biopsy and was diagnosed as lung adenocarcinoma with cT2aN1M1a Stage IVA (PUL). The pa...
Saved in:
Published in | Respiratory medicine case reports Vol. 46; p. 101929 |
---|---|
Main Authors | , , , , , , , , , |
Format | Report |
Language | English |
Published |
01.01.2023
|
Online Access | Get full text |
Cover
Loading…
Summary: | A 74-year-old man was referred to our hospital with an abnormal chest shadow. Computed tomography (CT) revealed a mass in the left upper lobe and interstitial pneumonia (IP). The patient underwent CT-guided needle biopsy and was diagnosed as lung adenocarcinoma with cT2aN1M1a Stage IVA (PUL). The patient was administered 6 cycles of CBDCA + nab-paclitaxel as first-line, 3 cycles of atezolizumab as second-line, and 8 cycles of S-1 as third-line treatment but finally showed tumor progression. Because comprehensive genome profiling test revealed KRAS G12C mutation, sotorasib was initiated as fourth-line treatment and showed tumor regression without exacerbation of pre-existing IP. |
---|---|
Bibliography: | ObjectType-Case Study-2 content type line 59 SourceType-Reports-1 ObjectType-Report-1 |
ISSN: | 2213-0071 2213-0071 |
DOI: | 10.1016/j.rmcr.2023.101929 |